Table 2.
Number of events, follow-up time, incidence rates and HRs for all study outcomes based on an IPTW population of 2063 (42%) ACEI/ARB users and 2816 (58%) nonusers
| Outcome | Analysis | Exposure group | Number of events | Follow-up time (years) |
Incidence rate (per 100 person-years) | HR (95% CI) | |
|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | ||||||
| Death, ischemic stroke or MI | ITT | ACEI/ARB | 695 | 1.50 ± 1.17 | 1.21 | 22.5 | 0.84 (0.76–0.93) |
| Nonuser | 1076 | 1.44 ± 1.14 | 1.16 | 26.6 | |||
| AT | ACEI/ARB | 256 | 0.72 ± 0.80 | 0.44 | 17.1 | 0.66 (0.57–0.76) | |
| Nonuser | 770 | 1.03 ± 1.00 | 0.71 | 26.5 | |||
| All-cause mortality | ITT | ACEI/ARB | 622 | 1.61 ± 1.20 | 1.33 | 18.8 | 0.83 (0.75–0.92) |
| Nonuser | 976 | 1.54 ± 1.18 | 1.27 | 22.6 | |||
| AT | ACEI/ARB | 206 | 0.74 ± 0.82 | 0.46 | 13.4 | 0.61 (0.52–0.72) | |
| Nonuser | 682 | 1.07 ± 1.02 | 0.75 | 22.6 | |||
| CV death | ITT | ACEI/ARB | 249 | 1.61 ± 1.20 | 1.33 | 7.5 | 0.74 (0.63–0.87) |
| Nonuser | 440 | 1.54 ± 1.18 | 1.27 | 10.2 | |||
| AT | ACEI/ARB | 85 | 0.74 ± 0.82 | 0.46 | 5.5 | 0.69 (0.54–0.89) | |
| Nonuser | 244 | 1.07 ± 1.02 | 0.75 | 8.1 | |||
| Ischemic stroke | ITT | ACEI/ARB | 82 | 1.54 ± 1.19 | 1.26 | 2.6 | 1.06 (0.79–1.43) |
| Nonuser | 102 | 1.48 ± 1.17 | 1.21 | 2.4 | |||
| AT | ACEI/ARB | 40 | 0.74 ± 0.81 | 0.45 | 2.6 | 1.06 (0.71–1.59) | |
| Nonuser | 69 | 1.06 ± 1.01 | 0.73 | 2.3 | |||
| MI | ITT | ACEI/ARB | 115 | 1.54 ± 1.18 | 1.25 | 3.6 | 0.88 (0.69–1.12) |
| Nonuser | 170 | 1.47 ± 1.15 | 1.21 | 4.1 | |||
| AT | ACEI/ARB | 47 | 0.73 ± 0.80 | 0.45 | 3.1 | 0.80 (0.57–1.13) | |
| Nonuser | 116 | 1.05 ± 1.00 | 0.72 | 3.9 | |||
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; AT, as treated; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; IPTW, inverse probability of treatment weighted; ITT, intention to treat; MI, myocardial infarction; SD, standard deviation.